Skip to main content
Sara Saberi, MD, Cardiology, Ann Arbor, MI

SaraSaberiMD

Cardiology Ann Arbor, MI

Adult Congenital Heart Disease, Cardiac Electrophysiology, Echocardiography, Cardiovascular Disease Genetics

Physician

Dr. Saberi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Saberi's full profile

Already have an account?

  • Office

    1500 E Medical Center Dr
    Ann Arbor, MI 48109
    Phone+1 734-936-4000

Education & Training

  • University of Michigan
    University of MichiganFellowship, Cardiovascular Disease, 2007 - 2010
  • University of Michigan
    University of MichiganResidency, Internal Medicine, 2003 - 2006
  • Wayne State University School of Medicine
    Wayne State University School of MedicineClass of 2003

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 2003 - 2025
  • American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Exercise Hemodynamics in Hypertrophic Cardiomyopathy Identify Risk of Incident Heart Failure but Not Ventricular Arrhythmias or Sudden Cardiac Death☆  
    Sharlene M Day, Sara Saberi, International Journal of Cardiology

Press Mentions

  • Cytokinetics Presents Positive Results from Cohort 4 of REDWOOD-HCM and Long-Term Results from FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session
    Cytokinetics Presents Positive Results from Cohort 4 of REDWOOD-HCM and Long-Term Results from FOREST-HCM at the American College of Cardiology 72nd Annual Scientific SessionMarch 4th, 2023
  • REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status
    REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health StatusOctober 7th, 2022
  • FDA Approves Camzyos for the Treatment of Obstructive Hypertrophic Cardiomyopathy
    FDA Approves Camzyos for the Treatment of Obstructive Hypertrophic CardiomyopathyMay 6th, 2022
  • Join now to see all

Professional Memberships